An open-label, uncontrolled, multicenter, multinational study on the efficacy and safety of administration of donor lymphocytes depleted of alloreactive T-cells (ATIR), through the use of TH9402 and light treatment in an ex vivo process, in patients receiving a CD34-selected peripheral blood stem cell graft from a related, haploidentical donor. - CR-AIR-004

Kiadis Pharma Netherlands B.V.0 个研究点目标入组 4 人开始时间: 待定最近更新: 2024年5月6日

适应症

试验速览

阶段: 2 期
状态: 已完成
发起方: Kiadis Pharma Netherlands B.V.
入组人数: 4

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Interventional

入排标准

年龄范围: 18 至 99（—）

入选标准

•Recipient Inclusion Criteria (any of the following)
•Initially, both patients with primary and secondary indications are eligible for the trial. During the trial accrual may be limited to the primary indications based on a recommendation made by the Independent Data Monitoring Committee (IDMC). ;Group 1: Primary Indications
•Acute Myeloid Leukemia (AML): AML in first remission with high risk features (secondary AML, FLT-3 mutation, complex karyotype, abn(3q), -5/5q-, -7/7q-, abn(12p), abn(17p), or other cytogenetic anomaly of similar poor prognosis, or need for 2 induction regimens to achieve a complete remission (CR)). All AML in second remission.
•Acute Lymphoblastic Leukemia (ALL): ALL in first remission with high-risk features (presenting leukocyte count > 30,000/mm3 for B-cell ALL or > 100,000/mm3 for T-cell ALL, karyotypes t(9;22), t(11;19), and t(4;11) biphenotypic leukemia, pro-B-ALL, late CR after induction therapy, rising MRD markers). All ALL in second remission.
•Myelodysplastic Syndrome (MDS): Transfusion-dependent MDS with low or intermediate-1 IPSS score, and all MDS with intermediate-2 or high IPSS score. Patients with more than 20% blasts in the marrow will be considered AML.
•Ph-positive chronic myeloid leukemia (CML): Patients with Ph-positive CML in first chronic phase (CP) who have failed (either resistant or intolerant) at least 2 tyrosine kinase inhibitors and any patient with the T315I mutation (irrespective of prior tyrosine kinase inhibitors).;Group 2: Secondary Indications
•- All AML not belonging to Group 1 in subsequent remission or with evidence of chemo-sensitive disease or,
•- Patients requiring 3 or more induction regimens to achieve a first remission or,
•- Patients with AML in hematologic remission who relapsed more than 2 years after allogeneic stem cell transplantation.
•ALL: All ALL not belonging to Group 1 in subsequent remission or with evidence of chemo-sensitive disease. Patients with ALL in hematologic remission who relapsed more than 2 years after allogeneic stem cell transplantation.
•Non-Hodgkin Lymphoma (NHL): All high grade and low grade Non-Hodgkin lymphoma (other than CLL and MM) in 2nd or 3rd remission (at least PR) after standard of care treatments including autologous stem cell transplantation.
•Chronic Myeloid Leukemia (CML): Patients with accelerated phase CML or CML in second or later chronic phase.
•Multiple Myeloma (MM): Secretory MM with or without osteolytic lesions concurrently not featuring extramedullary disease responsive to prior autologous stem cell transplantation(s) or at least one standard of care treatment (defined as 50% reduction of paraprotein in serum/plasma and/or 75% reduction of paraprotein in urine).
•Chronic Lymphocytic Leukemia (CLL):
•- CLL non-responsive or early relapsed (within 12 months) after a previous fludarabine- or equivalent purine-based regimen or,
•- CLL relapsed (within 24 months) after purine analogue combination therapy or treatment of similar efficacy (i.e. autologous stem cell transplantation) or,
•- CLL with p53 deletion/mutation (i.e. del 17p-) requiring treatment.
•CLL transformed to high grade lymphoma (Richter transformation) having demonstrated at least PR.
•MPS: Myeloproliferative disorders in transformation to acute leukemia or with progressive transfusion requirements or pancytopenia including atypical (Ph negative) chronic myeloid and neutrop

排除标准

•Recipient Exclusion Criteria (any of the following)
•AML in 1st CR with good risk karyotypes: AML M3 (t15; 17), AML M4Eo (inv 16), AML t (8; 21).
•MM featuring concurrent extramedullary disease or being non-responsive to prior therapy
•CML in blast crisis.
•CLL concurrently transformed into high-grade lymphoma and failing to demonstrate at least PR.
•NHL with concurrent bulky disease (>= 5 cm).
•Diffusing Capacity for Carbon Monoxide (DLCO) < 40% predicted.
•Left ventricular ejection fraction < 40% (evaluated by echocardiogram or MUGA).
•AST/SGOT > 2.5 x ULN (CTCAE grade II v3.0).
•Bilirubin > 1.5 x ULN (CTCAE grade II v3.0).
•Creatinine > 1.5 x ULN (CTCAE grade II v 3.0).
•HIV positive (Recipients who are positive for hepatitis B (HBV), hepatitis C (HCV) or human T-cell lymphotropic virus (HTLV-I/II) are not excluded from participation).
•Positive pregnancy test for women of childbearing age.
•Prior haploidentical PBSC or cord blood transplantation.
•Less than 2 years from a prior allogeneic stem cell transplantation.
•Estimated probability of surviving less than three months.
•Major anticipated illness or organ failure incompatible with survival from transplant.
•Severe psychiatric illness or mental deficiency sufficiently severe as to make compliance with the transplant treatment unlikely and informed consent impossible.
•Known allergy to any of the components of ATIR* (e.g., dimethyl sulfoxide).
•Any other condition which, in the opinion of the investigator, makes the patient ineligible for the study.;Donor Exclusion Criteria
•Medically uncontrolled coronary heart disease.
•Myocardial infarction within the last 3 months.
•History of uncontrolled seizures.
•History of malignancy (except basal cell or squamous carcinoma of the skin, positive PAP smear and subsequent negative follow up).
•Positive test result for any of the mandatory viral tests in the applicable region, except for a positive cytomegalovirus (CMV) result, which does not lead to exclusion.
•Presence of a transmissible disease (such as HIV positive), a major illness, a suspected systemic dysfunction and/or an active inflammatory or autoimmune disorder.
•Female donors who are pregnant or nursing.

研究者

发起方

Kiadis Pharma Netherlands B.V.

相似试验

进行中（未招募）

不适用

EUCTR2008-008198-73-BEKiadis Pharma Netherlands B.V.70

进行中（未招募）

不适用

EUCTR2008-008198-73-DEKiadis Pharma Netherlands B.V.70

进行中（未招募）

1 期

EUCTR2008-008198-73-GBKiadis Pharma Netherlands B.V.70

进行中（未招募）

不适用

EUCTR2008-008198-73-NLKiadis Pharma Netherlands B.V.70

进行中（未招募）

不适用

Clinical research study to assess the safety and effectiveness of alpha1-proteinase inhibitor (A1-PI) administered by intravenous application to patients with alpha1-proteinase deficiency and emphysema who have completed the 2-year treatment and observation period in the Phase III/IV Zemaira® CE1226_4001.Chronic augmentation and maintenance therapy in individuals with alpha1-proteinase inhibitor (A1-PI) deficiency and clinical evidence of emphysema.MedDRA version: 16.0Level: LLTClassification code 10001811Term: Alpha-1 proteinase inhibitor deficiencySystem Organ Class: 100000004850

EUCTR2007-007129-38-CZCSL Behring GmbH140